Related Experiment Video

Updated: Apr 26, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.0K

5-Aminosalicylic Acid Inhibits Acute Clostridium difficile Toxin A-Induced Colitis in Rats

Steven R Vigna1

  • 1Departments of Cell Biology & Medicine, Duke University Medical Center, P.O. Box 3011, Durham, NC 72210, USA ; VA Medical Center, Durham, NC 27705, USA.

International Journal of Inflammation
|July 22, 2014
PubMed

Insights

5-aminosalicylic acid (5-ASA) inhibits toxin A-induced colitis by blocking leukotriene B4 (LTB4) generation and substance P release. This suggests LTB4 activation of TRPV1 channels is crucial in toxin A colitis.

Area of Science:

  • Gastroenterology
  • Inflammation Research
  • Pharmacology

Background:

  • Toxin A is a major virulence factor in Clostridioides difficile infections, causing significant colonic inflammation.
  • Leukotriene B4 (LTB4) and TRPV1 channels are implicated in inflammatory processes within the colon.
  • The precise mechanisms by which 5-aminosalicylic acid (5-ASA) exerts its anti-inflammatory effects in toxin A-induced colitis are not fully elucidated.

Purpose of the Study:

  • To investigate the inhibitory effects of 5-aminosalicylic acid (5-ASA) on toxin A-induced leukotriene B4 (LTB4) generation and colitis in a rat model.
  • To explore the role of LTB4 and TRPV1 activation in the pathogenesis of toxin A colitis.
  • To determine if 5-ASA and its prodrug sulfasalazine can mitigate toxin A-induced colonic inflammation.

Main Methods:

  • Isolated colonic segments from rats were treated with toxin A, with or without pretreatment with 5-ASA or sulfapyridine, to measure LTB4 levels and assess inflammation.
  • Sulfasalazine was administered orally to rats for 5 days before toxin A challenge and subsequent inflammation assessment.
  • Capsaicin was used to induce direct TRPV1-mediated colitis to differentiate mechanisms.

Main Results:

  • 5-ASA pretreatment significantly inhibited toxin A-induced increases in colonic LTB4 concentration.
  • Both sulfasalazine and 5-ASA demonstrated significant inhibition of toxin A colitis, while sulfapyridine did not.
  • Toxin A stimulated substance P (SP) release, an effect also inhibited by sulfasalazine and 5-ASA.
  • 5-ASA did not protect against capsaicin-induced TRPV1-mediated colitis.

Conclusions:

  • Toxin A induces colonic inflammation through a pathway involving LTB4 generation, subsequent TRPV1 activation, and substance P release.
  • 5-ASA effectively disrupts this inflammatory cascade by inhibiting 5-lipoxygenase (5-LO), thereby reducing LTB4 production.
  • These findings support a critical role for LTB4 activation of TRPV1 in the pathogenesis of toxin A colitis, highlighting 5-ASA as a potential therapeutic agent.

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.1K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

8.4K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
700
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
840
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
590
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
999
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
745